Full View

Ischemic benefit and hemorrhage risk of ticagrelor-aspirin versus aspirin in patients with acute ischemic stroke or transient ischemic attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …
被引用次数：10 相关文章
[HTML] nih.gov

[HTML][HTML] Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - ncbi.nlm.nih.gov
BACKGROUND AND PURPOSE: In patients with acute mild-moderate ischemic stroke or
high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic …

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - diva-portal.org
Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background and Purpose:</jats: title>< jats: p> In patients with
acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial …
[PDF] researchgate.net

[PDF][PDF] Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - researchgate.net
BACKGROUND AND PURPOSE: In patients with acute mild-moderate ischemic stroke or
high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic …

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - europepmc.org
Background and purpose In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - Am Heart Assoc
BACKGROUND AND PURPOSE: In patients with acute mild-moderate ischemic stroke or
high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic …
[PDF] diva-portal.org

[PDF][PDF] Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

SC Johnston, P Amarenco, M Aunes, H Denison… - Stroke, 2021 - diva-portal.org
BACKGROUND AND PURPOSE: In patients with acute mild-moderate ischemic stroke or
high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic …